Literature DB >> 19800199

Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer.

Sarah M Eck1, Jessica S Blackburn, Adam C Schmucker, Peter S Burrage, Constance E Brinckerhoff.   

Abstract

Similarities in the pathologies of autoimmune diseases and cancer have been noted for at least 30 years. Inflammatory cytokines and growth factors mediate cell proliferation, and proteinases, especially the collagenase, Matrix Metalloproteinase-1 (MMP-1), contribute to disease progression by remodeling the extracellular matrix and modulating the microenvironment. This review focuses on two cancers (melanoma and breast) and on the autoimmune disorder, rheumatoid arthritis (RA), and discusses the activated stromal cells found in these diseases. MMP-1 was originally thought to function only to degrade interstitial collagens, but recent studies have revealed novel roles for MMP-1 involving the G protein-coupled receptors: the chemokine receptor, CXCR-4, and Protease Activated Receptor-1 (PAR-1). Cooperativity between MMP-1 and CXCR4/SDF-1 signaling influences the behavior of activated fibroblasts in both RA and cancer. Further, MMP-1 is a vital part of an autocrine/paracrine MMP-1/PAR-1 signal transduction axis, a function that amplifies its potential to remodel the matrix and to modify cell behavior. Finally, new therapeutic agents directed at MMP-1 and G protein-coupled receptors are emerging. Even though these agents are more specific in their targets than past therapies, these targets are often shared between RA and cancer, underscoring fundamental similarities between autoimmune disorders and some cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800199      PMCID: PMC2783549          DOI: 10.1016/j.jaut.2009.09.011

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  88 in total

Review 1.  International Union of Pharmacology. XXVIII. Proteinase-activated receptors.

Authors:  Morley D Hollenberg; Steven J Compton
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

Review 2.  Retinoids and rexinoids for the 21st century: a brave new world for arthritis.

Authors:  Constance E Brinckerhoff; Michael B Sporn
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

Review 3.  Proteolytic and non-proteolytic migration of tumour cells and leucocytes.

Authors:  Peter Friedl; Katarina Wolf
Journal:  Biochem Soc Symp       Date:  2003

Review 4.  Mechanism of thrombin-induced angiogenesis.

Authors:  M E Maragoudakis; N E Tsopanoglou; P Andriopoulou
Journal:  Biochem Soc Trans       Date:  2002-04       Impact factor: 5.407

Review 5.  Tissue factor, thrombin, and cancer.

Authors:  Frederick R Rickles; Steven Patierno; Patricia M Fernandez
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

6.  Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts.

Authors:  F Hirano; A Kobayashi; Y Hirano; Y Nomura; E Fukawa; I Makino
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

7.  PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice.

Authors:  Tomoko Shiojiri; Koichiro Wada; Atsushi Nakajima; Kazufumi Katayama; Atsuhito Shibuya; Chiho Kudo; Takashi Kadowaki; Tadanori Mayumi; Yoshiaki Yura; Yoshinori Kamisaki
Journal:  Eur J Pharmacol       Date:  2002-07-19       Impact factor: 4.432

8.  Bone marrow-derived progenitor cells in pulmonary fibrosis.

Authors:  Naozumi Hashimoto; Hong Jin; Tianju Liu; Stephen W Chensue; Sem H Phan
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

9.  Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma.

Authors:  Salvatore Cuzzocrea; Emanuela Mazzon; Laura Dugo; Nimesh S A Patel; Ivana Serraino; Rosanna Di Paola; Tiziana Genovese; Domenico Britti; Massimo De Maio; Achille P Caputi; Christoph Thiemermann
Journal:  Arthritis Rheum       Date:  2003-12

10.  Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis.

Authors:  Blake C Beehler; Yong-Jiang Hei; Simon Chen; John A Lupisella; Jacek Ostrowski; John E Starrett; David Tortolani; Kenneth M Tramposch; Peter R Reczek
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

View more
  27 in total

1.  What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?

Authors:  Ferdinando Mannello
Journal:  BMC Med       Date:  2011-08-11       Impact factor: 8.775

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 3.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 4.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

5.  Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis.

Authors:  Rajesh Rajaiah; Muraly Puttabyatappa; Swamy K Polumuri; Kamal D Moudgil
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

Review 6.  The functional role of reactive stroma in benign prostatic hyperplasia.

Authors:  Isaiah G Schauer; David R Rowley
Journal:  Differentiation       Date:  2011-06-12       Impact factor: 3.880

7.  G protein-coupled receptors engage the mammalian Hippo pathway through F-actin: F-Actin, assembled in response to Galpha12/13 induced RhoA-GTP, promotes dephosphorylation and activation of the YAP oncogene.

Authors:  Laura Regué; Fan Mou; Joseph Avruch
Journal:  Bioessays       Date:  2013-03-01       Impact factor: 4.345

8.  Prognostic value of matrix metalloprotease-1/protease-activated receptor-1 axis in patients with prostate cancer.

Authors:  Jian Wang; Dingyi Liu; Wenlong Zhou; Mingwei Wang; Weimu Xia; Qi Tang
Journal:  Med Oncol       Date:  2014-05-08       Impact factor: 3.064

9.  Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Authors:  Molly H Jenkins; Shannon M Steinberg; Matthew P Alexander; Jan L Fisher; Marc S Ernstoff; Mary Jo Turk; David W Mullins; Constance E Brinckerhoff
Journal:  Pigment Cell Melanoma Res       Date:  2014-03-06       Impact factor: 4.693

10.  Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis.

Authors:  C J Foley; M Fanjul-Fernández; A Bohm; N Nguyen; A Agarwal; K Austin; G Koukos; L Covic; C López-Otín; A Kuliopulos
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.